Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study

References

• Bringsvor HB, Skaug K, Langeland E, et al. Symptom burden and self-management in persons with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:365–373. doi:10.2147/COPD.S15142829416327
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2019 Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed 1218, 2018.
   Google Scholar
• Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J. 2006;27(2):397–412. doi:10.1183/09031936.06.0002580516452599
   PubMed Web of Science ®Google Scholar
• American Thoracic Society. The global burden of lung disease; 2014 Available from: http://foundation.thoracic.org/news/global-burden.php. Accessed 829, 2018.
   Google Scholar
• Chapman KR, Mannino DM, Soriano JB, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J. 2006;27(1):188–207. doi:10.1183/09031936.06.0002450516387952
   PubMed Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245. doi:10.2147/CEOR.S3432123818799
   PubMedGoogle Scholar
• COPD Foundation. COPD foundation’s pocket consultant guide; 2017 update Available from: https://www.copdfoundation.org/Praxis/Resource-Repository/Treatment.aspx. Accessed 329, 2018.
   Google Scholar
• Reddel HK, Bateman ED, Becker A, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respir J. 2015;46(3):622–639. doi:10.1183/13993003.00853-201526206872
   PubMed Web of Science ®Google Scholar
• Global Initative for Asthma. Global strategy for asthma management and prevention; 2018 Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed 731, 2018.
   Google Scholar
• Cardoso J, Coelho R, Rocha C, Coelho C, Semedo L, Bugalho Almeida A. Prediction of severe exacerbations and mortality in COPD: the role of exacerbation history and inspiratory capacity/total lung capacity ratio. Int J Chron Obstruct Pulmon Dis. 2018;13:1105–1113. doi:10.2147/COPD.S15584829670346
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa02132214999112
   PubMed Web of Science ®Google Scholar
• Oga T, Tsukino M, Hajiro T, et al. Multidimensional analyses of long-term clinical courses of asthma and chronic obstructive pulmonary disease. Allergol Int. 2010;59(3):257–265. doi:10.2332/allergolint.10-RA-018420657164
   PubMedGoogle Scholar
• Singh D, Maleki-Yazdi MR, Tombs L, Iqbal A, Fahy WA, Naya I. Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol. Int J Chron Obstruct Pulmon Dis. 2016;11:1413–1424. doi:10.2147/COPD.S10161227445468
   PubMed Web of Science ®Google Scholar
• Anzueto AR, Vogelmeier CF, Kostikas K, et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1325–1337. doi:10.2147/COPD.S13330728496316
   PubMed Web of Science ®Google Scholar
• Maleki-Yazdi M. Clinically important deterioration in patients with COPD using umeclidinium/vilanterol, tiotropium or placebo: pooled data. Eur Respir J. 2015;46:P1001.
   Web of Science ®Google Scholar
• Singh D, D’Urzo AD, Chuecos F, Muñoz A, Gil EG. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol. Respir Res. 2017;18(1):106. doi:10.1186/s12931-017-0583-028558833
   PubMed Web of Science ®Google Scholar
• Anzueto AR, Kostikas K, Mezzi K, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respir Res. 2018;19(1):121. doi:10.1186/s12931-018-0830-z29925383
   PubMed Web of Science ®Google Scholar
• Lipson D, Compton C, Naya I. Prevention of early worsening of COPD with umeclidinium open triple therapy compared with inhaled corticosteroid/long-acting β2-agonist alone: a pooled post hoc analysis. Am J Respir Crit Care Med. 2017;195:A3608. doi:10.1164/rccm.201701-0150WS
   Web of Science ®Google Scholar
• Naya I, Compton C, Ismaila A, et al. Preventing clinically important deterioration with single-inhaler triple therapy in COPD. ERJ Open Res. 2018;4:00047–2018.30302335
   PubMedGoogle Scholar
• Naya I, Tombs L, Lipson DA, Compton C. Preventing clinically important deterioration of COPD with addition of umeclidinium to inhaled corticosteroid/long-acting β2-agonist therapy: an integrated post hoc analysis. Adv Ther. 2018;35(10):1626–1638. doi:10.1007/s12325-018-0771-430191464
   PubMed Web of Science ®Google Scholar
• Vestbo J; the TORCH Study Group. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J. 2004;24(2):206–210.15332386
   PubMed Web of Science ®Google Scholar
• Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.0001430415219010
   PubMed Web of Science ®Google Scholar
• UK Department of Health and Social Care. NHS references costs 2015 to 2016; 2016 Available from: https://www.gov.uk/government/publications/nhs-reference-costs-2015-to-2016. Accessed 430, 2018.
   Google Scholar
• Personal Social Services Research Unit. Unit costs of health and social care; 2011–2016 Available from: https://www.pssru.ac.uk/research/354. Accessed 430, 2018.
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108.9366889
   PubMed Web of Science ®Google Scholar
• Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016;71(6):493–500. doi:10.1136/thoraxjnl-2015-20778227030578
   PubMed Web of Science ®Google Scholar
• Punekar YS, Shukla A, Müllerova H. COPD management costs according to the frequency of COPD exacerbations in UK primary care. Int J Chron Obstruct Pulmon Dis. 2014;9:65–73. doi:10.2147/COPD.S5441724426781
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Inflation and price indices; 2018 Available from: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/l55o/mm23. Accessed 619, 2018.
   Google Scholar
• World Health Organization. CHOosing interventions that are cost effective (WHO-CHOICE): country-specific unit costs; 2008 Available from: http://www.who.int/choice/country/country_specific/en/. Accessed 54, 2018.
   Google Scholar
• Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.0011170718216052
   PubMed Web of Science ®Google Scholar
• Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res. 2010;11(1):122. doi:10.1186/1465-9921-11-6220831787
   PubMed Web of Science ®Google Scholar
• Naya IP, Tombs L, Muellerova H, Compton C, Jones PW. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir Res. 2018;19(1):222. doi:10.1186/s12931-018-0928-330453972
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554. doi:10.1056/NEJMoa080580018836213
   PubMed Web of Science ®Google Scholar
• Rabe KF, Halpin D, Martinez F, et al. Predicting long-term outcomes and future deterioration in COPD with a composite endpoint: post hoc analysis of the UPLIFT study. Am J Respir Crit Care Med. 2017;195:A2717. doi:10.1164/rccm.201701-0150WS
   Web of Science ®Google Scholar
• Han MK, Halpin DMG, Martinez FJ, et al. A composite endpoint of clinically important deterioration in chronic obstructive pulmonary disease and its association with increased mortality: a post hoc analysis of the UPLIFT study. Am J Respir Crit Care Med. 2018;197:A4245.
   Web of Science ®Google Scholar
• Gedebjerg A, Szépligeti SK, Wackerhausen L-MH, et al. Prediction of mortality in patients with chronic obstructive pulmonary disease with the new Global Initiative for Chronic Obstructive Lung Disease 2017 classification: a cohort study. Lancet Respir Med. 2018;6(3):204–212. doi:10.1016/S2213-2600(18)30002-X29331311
   PubMed Web of Science ®Google Scholar